Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$204.70
-0.7%
$214.17
$176.57
$244.81
$362.51B0.327.09 million shs890,445 shs
Astrazeneca Plc stock logo
AZN
Astrazeneca
$185.03
+2.1%
$195.55
$132.32
$212.71
$287.22B0.262.73 million shs526,753 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$113.86
+0.6%
$117.51
$73.31
$125.14
$281.35B0.1811.19 million shs1.36 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.49
+0.1%
$27.17
$21.97
$28.75
$150.83B0.3542.53 million shs10.03 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$145.67
+0.3%
$149.16
$127.35
$160.59
$38.22B0.5813.03 million shs2.58 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.25%+4.19%-1.28%-5.03%+5.14%
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.77%-2.89%-10.80%-3.25%+25.79%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.81%+2.80%-6.14%-4.34%+36.65%
Pfizer Inc. stock logo
PFE
Pfizer
+0.29%-0.09%-6.85%-1.52%+10.73%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
+0.10%+1.02%-1.03%-6.88%+5.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$204.70
-0.7%
$214.17
$176.57
$244.81
$362.51B0.327.09 million shs890,445 shs
Astrazeneca Plc stock logo
AZN
Astrazeneca
$185.03
+2.1%
$195.55
$132.32
$212.71
$287.22B0.262.73 million shs526,753 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$113.86
+0.6%
$117.51
$73.31
$125.14
$281.35B0.1811.19 million shs1.36 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.49
+0.1%
$27.17
$21.97
$28.75
$150.83B0.3542.53 million shs10.03 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$145.67
+0.3%
$149.16
$127.35
$160.59
$38.22B0.5813.03 million shs2.58 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.25%+4.19%-1.28%-5.03%+5.14%
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.77%-2.89%-10.80%-3.25%+25.79%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.81%+2.80%-6.14%-4.34%+36.65%
Pfizer Inc. stock logo
PFE
Pfizer
+0.29%-0.09%-6.85%-1.52%+10.73%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
+0.10%+1.02%-1.03%-6.88%+5.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.85
Moderate Buy$252.9023.55% Upside
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.85
Moderate Buy$205.3310.97% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.1812.57% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.748.50% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.73
Moderate Buy$145.24-0.30% Downside

Current Analyst Ratings Breakdown

Latest ABBV, MRK, PFE, XLV, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/4/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Reiterated RatingHold (C+)
5/1/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingBuy$249.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetOverweight$150.00 ➝ $145.00
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
4/30/2026
AbbVie Inc. stock logo
ABBV
AbbVie
UpgradeHoldStrong-Buy
4/30/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetBuy$262.00 ➝ $265.00
4/30/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$270.00 ➝ $278.00
4/30/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingOverweight$240.00
4/30/2026
AbbVie Inc. stock logo
ABBV
AbbVie
UpgradeNeutralBuy$234.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B5.92$14.90 per share13.74($1.83) per share-111.86
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.89$13.04 per share14.19$30.55 per share6.06
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.33$11.50 per share9.90$21.22 per share5.37
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.41$4.43 per share5.98$15.26 per share1.74
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$2.03101.0012.590.725.79%-911.57%13.43%N/A
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$5.9127.8116.081.5117.19%30.86%12.68%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5532.0911.562.2413.59%26.84%10.74%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3619.509.39N/A12.42%20.48%8.86%N/A
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/AN/A

Latest ABBV, MRK, PFE, XLV, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
4/29/2026Q1 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion
4/29/2026Q1 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.52$2.58+$0.06$0.9850$14.93 billion$15.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.923.38%+6.80%340.89%53 Years
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.35%+2.30%73.43%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.99%+5.75%95.77%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.49%-13.20%126.47%16 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.501.72%N/AN/AN/A

Latest ABBV, MRK, PFE, XLV, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.42%5/8/20265/8/20266/12/2026
2/19/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.733.32%4/15/20264/15/20265/15/2026
2/10/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$1.59501.56%2/20/20262/20/20263/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.67
0.56
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.52
0.91
0.71
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.54
1.30
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.16
0.87
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.69 billion5.65 billionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A262.11 millionN/ANot Optionable

Recent News About These Companies

Close-up of semiconductor chips and silicon wafer, representing AMD and AI-driven growth in the semiconductor industry.
What Q1 Earnings Could Mean for the S&P 500 Uptrend (XLV)
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$204.70 -1.41 (-0.68%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$185.03 +3.79 (+2.09%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$113.86 +0.71 (+0.63%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$26.48 +0.04 (+0.13%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$145.67 +0.37 (+0.26%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.